Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nerisopam SCHEMBL8349837 | 0.86 | CYP1A2 (0.63) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Nerisopam SCHEMBL1004757 | 0.86 | CYP1A2 (0.63) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7439770 | 0.86 | MAPT (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL6420733 | 0.86 | MEN1 (0.52) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7410880 | 0.86 | PDGFRB (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL15985265 | 0.86 | MAPK10 (0.52) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17020991 | 0.85 | CHEK1 (0.50) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15985262 | 0.84 | CYP1A2 (0.41) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10884494 | 0.83 | CYP3A4 (0.48) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16913376 | 0.83 | CHEK1 (0.48) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890147-B2 | 2,3-benzodiazepines | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2018-02-13 | — | — | US | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| CN-104755473-B | 2,3 benzodiazepine * | 拜耳医药股份有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| EP-2958909-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015121226-A1 | 6-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121268-A1 | 1-PHENYL-3H-2,3-BENZODIAZEPINES AND THEIR USE AS BROMODOMAIN INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121230-A1 | 9-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-23 | — | — | US | disclosed |
| WO-2014202578-A1 | SUBSTITUTED PHENYL-2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014128067-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128067-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BRD4, BRDT, BICRA | CHEK1 501/4885CYP1A2 1412/4885CYP3A4 1651/4885 |
| US-20150203483-A1 | 2,3-BENZODIAZEPINES | BRD4, BET1, BRDT | CHEK1 714/4885CYP1A2 859/4885CYP3A4 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.